What is full-scale CRP?

C-reactive protein (CRP) is a pentameric protein consisting of five monomers secreted by the liver with a molecular weight of approximately 120 kDa and its monomer consists of 224 amino acids with a molecular weight of approximately 25 kDa. And it is an acute phase protein synthesised by hepatocytes and can be elevated by a variety of factors including infection and tissue damage such as acute myocardial infarction, pneumonia and surgery.

Full scale of C-Reactive Protein tests, including: High Sensitivity C-Reactive Protein (hsCRP) and Conventional C-Reactive Protein (CRP).Conventional CRP and Hs-CRP are defined below:

CRP：Serum β-globulin, with a molecular mass of 115-140 KD, is a cyclic pentaglobule composed of five identical subunits bound by non-covalent bonds, synthesised by hepatocytes, and measured in a variety of bodily fluids, including human serum, cerebrospinal fluid, and pleural and abdominal fluids.

Hs-CRP：The detection of CRP by high-sensitivity methods allows the detection of changes in CRP at low concentrations, which are strongly associated with the development of infections and cardiovascular diseases in newborns.

So we can see that Full scale C-reactive protein is used for risk assessment of cardiovascular disease and screening for the presence of acute and chronic inflammation or tissue necrosis in the body.

Clinical application of full-scale CRP

The plasma half-life of CRP is approximately 19 hours and is constant in all health and disease conditions, so the only determinant of circulating CRP concentration is the rate of synthesis, which is reduced almost exclusively by hepatic failure.

CRP begins to rise 6-8h after the onset of infection and reaches a peak in 24-48h, with peak values up to hundreds of times normal, and then declines sharply after the infection is eliminated, returning to normal within a week.

Conventional CRP and high-sensitivity CRP have different clinical applications as follows:

CRP:

① A basis for experimental examination of infectious diseases. Particularly suitable for patients with fever to be checked, comatose patients, elderly patients, demented patients, children and other patients;

② An essential tool for the differential diagnosis of viral or bacterial infections, allowing dynamic monitoring of the course and determination of antibiotic efficacy.

Hs-CRP：

① Elevated hs-CRP is recommended as a risk enhancement factor for cardiovascular disease and can be used to screen high-risk populations of cardiovascular disease;

② Suitable for paediatric infection diagnostic needs to reduce the risk of drug-resistant neonatal deaths;

③ Hs-CRP can be used to independently evaluate aging-related cardiac events.

Factors affecting full-scale CRP

Increased Full-scale CRP levels may be due to:

Inflammation and Infection

(Upper respiratory tract infection, pneumonia, bronchitis, meningitis;Bacterial/Viral/Fungal infection;)

Connective Tissue Disease

(Rheumatoid arthritis, Systemic lupus erythematosus)

Oncological Disease

(Malignant tumours develop an acute phase reaction during disease progression)

Partial Cardiovascular Disease

(Acute heart failure, Myocarditis, Myocardial Infarction, Cerebral Thrombosis)

Tissue Damage

(Various surgeries, or angina pectoris or myocardial infarction due to myocardial ischaemia)

Summary

CRP is clinically significant for screening infections and organic lesions and monitoring responses to the treatment of infections and inflammation. In addition, as a disease marker, the plasma concentration of CRP is well associated with the severity, progression and prognosis of a variety of diseases with different pathologies, including inflammation and cardiovascular diseases.

The ReLIA Full-Scale CRP Immunoassay is CE-marked cleared. For more details on ReLIA Full-Scale CRP Immunoassay products and prices please contact us at marketing@ReLIAchina.com.

References

[1 ]Tillet W, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J Exp Med, 1930, 52(4): 561–571.

[2] Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med, 1999, 17(6): 1019–1025.

[3] Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340(2): 115–126.

[4] Zhang YX, Cliff WJ, Schoefl GI, et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis, 1999, 145(2): 375–379.

[5] Taubes G. Cardiovascular disease. Does inflammation cutto the heart of the matter? Science, 2002, 296(5566): 242–245.

[6] De Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol, 2007, 16(1): 14–21.